"Hepacivirus" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A genus of FLAVIVIRIDAE causing parenterally-transmitted HEPATITIS C which is associated with transfusions and drug abuse. Hepatitis C virus is the type species.
| Descriptor ID |
D016174
|
| MeSH Number(s) |
B04.450.410 B04.820.250.475
|
| Concept/Terms |
Hepacivirus- Hepacivirus
- Hepaciviruses
- Hepatitis C-Like Viruses
- Hepatitis C Like Viruses
- Hepatitis C-Like Virus
|
Below are MeSH descriptors whose meaning is more general than "Hepacivirus".
Below are MeSH descriptors whose meaning is more specific than "Hepacivirus".
This graph shows the total number of publications written about "Hepacivirus" by people in this website by year, and whether "Hepacivirus" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 0 | 1 | 1 |
| 1995 | 4 | 1 | 5 |
| 1996 | 1 | 0 | 1 |
| 1997 | 2 | 2 | 4 |
| 1998 | 1 | 1 | 2 |
| 1999 | 0 | 5 | 5 |
| 2000 | 0 | 1 | 1 |
| 2001 | 2 | 2 | 4 |
| 2002 | 3 | 0 | 3 |
| 2003 | 2 | 1 | 3 |
| 2004 | 1 | 2 | 3 |
| 2005 | 5 | 1 | 6 |
| 2006 | 3 | 1 | 4 |
| 2007 | 1 | 4 | 5 |
| 2008 | 3 | 0 | 3 |
| 2009 | 4 | 3 | 7 |
| 2010 | 2 | 3 | 5 |
| 2011 | 7 | 3 | 10 |
| 2012 | 7 | 8 | 15 |
| 2013 | 10 | 2 | 12 |
| 2014 | 7 | 9 | 16 |
| 2015 | 11 | 3 | 14 |
| 2016 | 9 | 6 | 15 |
| 2017 | 13 | 7 | 20 |
| 2018 | 10 | 4 | 14 |
| 2019 | 4 | 6 | 10 |
| 2020 | 3 | 5 | 8 |
| 2021 | 2 | 7 | 9 |
| 2022 | 2 | 20 | 22 |
| 2023 | 2 | 11 | 13 |
| 2024 | 0 | 3 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Hepacivirus" by people in Profiles.
-
Hepatitis C and its treatment in patients with psoriasis: a propensity-matched case-control study. Arch Dermatol Res. 2024 Aug 29; 316(8):580.
-
Implementation of Universal Hepatitis C Virus Screening in a Tertiary Cancer Center. J Natl Compr Canc Netw. 2024 05 10; 22(2 D).
-
Sofosbuvir-velpatasvir in children 3-17 years old with hepatitis C virus infection. J Pediatr Gastroenterol Nutr. 2024 Jun; 78(6):1342-1354.
-
GSK-3? as a Potential Coordinator of Anabolic and Catabolic Pathways in Hepatitis C Virus Insulin Resistance. Intervirology. 2024; 67(1):6-18.
-
Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease: Synopsis of the Kidney Disease: Improving Global Outcomes 2022 Clinical Practice Guideline. Ann Intern Med. 2023 12; 176(12):1648-1655.
-
ATAD1 inhibits hepatitis C virus infection by removing the viral TA-protein NS5B from mitochondria. EMBO Rep. 2023 11 06; 24(11):e56614.
-
Associations of Race and Ethnicity with Hepatocellular Carcinoma, Decompensation, and Mortality in US Veterans with Cirrhosis. Cancer Epidemiol Biomarkers Prev. 2023 08 01; 32(8):1069-1078.
-
Regional Differences in Clinical Presentation and Prognosis of Patients With Post-Sustained Virologic Response Hepatocellular Carcinoma. Clin Gastroenterol Hepatol. 2024 01; 22(1):72-80.e4.
-
Immune Checkpoint Inhibitors Suppress Hepatitis C Virus Replication in Infected Patients With Solid Tumors. Am J Gastroenterol. 2023 09 01; 118(9):1609-1617.
-
Hepatocellular Carcinoma Incidence Threshold for Surveillance in Virologically Cured Hepatitis C Individuals. Clin Gastroenterol Hepatol. 2024 01; 22(1):91-101.e6.